Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Payables (2021 - 2025)

Zymeworks' Payables history spans 5 years, with the latest figure at $36.3 million for Q4 2025.

  • On a quarterly basis, Payables fell 39.26% to $36.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.3 million, a 39.26% decrease, with the full-year FY2025 number at $36.3 million, down 39.26% from a year prior.
  • Payables hit $36.3 million in Q4 2025 for Zymeworks, up from $34.4 million in the prior quarter.
  • Over the last five years, Payables for ZYME hit a ceiling of $87.5 million in Q4 2022 and a floor of $31.0 million in Q2 2025.
  • Historically, Payables has averaged $52.6 million across 5 years, with a median of $51.7 million in 2024.
  • Biggest five-year swings in Payables: surged 39.3% in 2022 and later plummeted 47.42% in 2023.
  • Tracing ZYME's Payables over 5 years: stood at $62.8 million in 2021, then soared by 39.3% to $87.5 million in 2022, then plummeted by 47.42% to $46.0 million in 2023, then soared by 30.11% to $59.8 million in 2024, then plummeted by 39.26% to $36.3 million in 2025.
  • Business Quant data shows Payables for ZYME at $36.3 million in Q4 2025, $34.4 million in Q3 2025, and $31.0 million in Q2 2025.